Method for treatment of staphylococcus bacteriolactia in women

FIELD: medicine, pediatrics, obstetrics.

SUBSTANCE: method involves administration of preparations balans-narine-f and calcemin. Carrying out this therapy provides decreasing the content of staphylococci in breast milk, increasing the sterility period of milk based on reducing cellular membranes penetrability and to diminish probability in development complications in treatment of bacteriolactia in nursing women. Invention can be used in treatment of staphylococcus bacteriolactia in women.

EFFECT: improved method of treatment.

1 tbl, 2 ex

 

The invention relates to medicine, primarily to Pediatrics, and is intended to ensure bakteriologie of lactating women.

It is known that in the pathogenesis of bakteriologie lactating women plays a major role staphylococcal infection. Within the first 5 days of life 40-90% of newborns infected by staphylococci. If this disease of the newborn closely associated with infection of the mother, the care and sanitary-hygienic characteristics of the environment. Widespread virulent antibiotic-resistant strains of staphylococci with high adaptive capacity, determines their distribution in the environment and humans. In women during pregnancy and lactation marked depression of the immune system-related decline in cellular immune response. These changes are a natural reaction, contributing to long-term coexistence of two genetically different organisms, ensuring the normal course of pregnancy and childbirth. All indicators of immunological reactivity restored to the 7th day postpartum period, however, associated with extragenital pathology or complications normal pregnancy and childbirth occur even more profound changes in the body's immune system modernity% of children are receiving breast milk. Due to the inherent microbial colonization of the newborn is extremely large value of breastfeeding, which ensures the continuation of the immunological relationship of the child with his mother. Through breast milk is transferred neutralized antigens and protective antibodies, proteins milk least Allegheny, nutrients are most appropriate for the enzymatic systems of the digestive system of the child.

However, the microflora of breast milk can be a real threat to the development of bacterial inflammatory process in children or dysbiosis, and the degree of dysbacteriosis of an organism of the child matches the contamination of milk in lactating women (1). Cause of particular concern for the analyses of donor milk in the Russian Federation: in General, the percentage of unsatisfactory samples is 4.5%, but the number of objects of RF ranges from 16.6 to 40% (2). In case of detection of infection milk breastfeeding is terminated: 1) upon detection of a massive growth of pathogenic staphylococci; 2) when re-allocation of even a single colonies of Enterobacteriaceae; 3) with a massive selection of any kind of staphylococci and the presence of intestinal disorders in children (3). In other cases, bakteriologie used antibacterial therapy with chemotherapeutic agents, cause the first violation of microbiocenosis of the body, allergic and toxic complications (4).

Thus, the practical significance assessment of bacteriological contamination of breast milk, and development of effective and safe method of correction of the staphylococcal bakteriologie of lactating women.

There is a method of treatment of staphylococcal-bakteriologie using antibiotics ampicillino series, prototype (4). Lactating women upon detection of staphylococci in human milk at a concentration of 103and above, and in the case of pathogenicity of the pathogen, regardless of the content was prescribed ampicillin trihydrate 0.5 to 1 tablet 3 times daily by mouth for 10 days. At the time of treatment the child received no breast milk, were transferred to artificial feeding or breast milk saivas and subjected to boiling. As a result of treatment there was a decrease in the content of staphylococci in milk to sterility in 63.3% of cases.

However, antibiotic therapy at the same time caused the development of dysbiosis in lactating women that influenced the microbial background of the child's body. A significant drawback of the proposed therapy was a drastic interruption of breast-feeding and the removal of the child for the period from 10 to 12 days on artificial feeding, which has adversely impacted on the situation of the Institute of digestive system of the child, created lighter conditions for obtaining food, and often led to a complete cessation of breastfeeding. Antibiotic therapy is often complicated by allergic and toxic reactions, which affects the health of a nursing woman, and child. Preservation of breastfeeding on a background of antibacterial therapy in women is accompanied by active selection of antibiotics through breast milk and causing the child development clinic dysbiosis (4-6).

The invention consists in that the treatment of staphylococcal-bakteriologie of lactating women is carried out by receiving an antibacterial agent, characterized in that as an antibacterial agent used balance-Narine-f and impose additional calcemin.

Effect: increase the number of women with a sterile breast milk, reducing the period of decrease in the content of staphylococci in the breast milk of nursing women, the increase in the period of its sterility by reducing the permeability of the cell membrane, reduction of complications in the treatment of bakteriologie of lactating women.

Experimental and clinical studies have demonstrated that microbial background of the human body is formed in the gastrointestinal tract, and dysbiosis in some biologists is a mini-zones of the human body is directly proportional of the total microflora (2). As a result of pregnancy and childbirth microbial changes the background of the woman's body. Modern environmental conditions dramatically worsened the microbial Association of soil, water, and air, respectively, of the population. So the body of the modern woman in lactation is characterized by an undeniable violation of microbial balance, including breast milk. Therefore, from our point of view for the normalization of bacteriological composition of milk is necessary: 1) to normalize the content in the first place, staphylococci in the intestinal microbiocenosis lactating women; 2) to stabilize the cell wall complex of essential macro - and micronutrients. To solve the first part of the task we used bacterial-enzyme with antibacterial effect balance-Narine-f containing waste products acidophilus lactobacilli with high bactericidal activity against a number of pathogenic microorganisms, including staphylococci. Containing natural products of the metabolism of Lactobacillus acidophilus product is completely harmless, has no contraindications and is well tolerated. To solve the second task was applied macro - and microelement drug "Calcemin". It is necessary concomitant use of two tools, because the assignment of one balance-Narine-f does not guarantee a strong sight of the value of breast milk, as in the postpartum period in terms of lactation a woman's body is in a state of deficiency of macro - and microelements, which can lead to further shortages of protective forces of an organism and the resumption of bakteriologie. Use only one calamine also may not affect the content of Staphylococcus aureus in a woman's body due to the absence of antimicrobial action.

The method is as follows. In lactating women was determined by the content in breast milk bacteria of different groups, including staphylococci, classical bacteriological method (3). Upon detection of pathogenic staphylococci in any concentration and content of non-pathogenic staphylococci groups at a concentration of 103and above the woman was prescribed a balance-Narine-f 10 ml 2 times a day for 10 days and calcemin 1 tablet 1 time per day for 25 days.

All proposed method were treated with 180 women who were found elevated concentrations of staphylococci in human milk. There was marked clinical effect, confirmed by clinical and laboratory methods of research and long-term (10 months) observation after treatment.

Made of our study showed that 98% of women with an infected breast milk as a result of the treatment was observed considerable the e changes in the bacteriological composition of breast milk may be reduced concentrations of staphylococci to 10 2and the absence of pathogenic staphylococci groups (table).

Clinical example 1. Patient PTN., 27 years. Diagnosis: Staphylococcus bacteriology. Perforada, pregnancy proceeded with preeclampsia mild, delivery naturally. The age of the child 2 months. Bacteriological examination of breast milk allocated: St. aureus in the left and right breast in a concentration of 1×102; St. saprophyticus in the left gland 2×102in the right - 3×102; Micrococcus spp. in both breast 1×102. Treatment: Balance-Narine-f 10 ml 2 times a day by mouth for 10 days, calcemin 1 tablet 1 time per day by mouth for 25 days. Treatment results: bacteriological examination of breast milk allocated: St. saprophyticus in the left and right breast at a concentration of 2×102and 4×102respectively (without pathology).

Clinical example 2. Patient REV, 26 years. Diagnosis: Staphylococcus bacteriology. Perforada, pregnancy proceeded with preeclampsia mild, delivery by caesarean section. The age of the child 2, 5 months. Bacteriological examination of breast milk allocated: St. aureus in the left and right breast in a concentration of 1×102and 14×102respectively; St. saprophyticus in the left gland is not found, right - 1×10 . Treatment: Balance-Narine-f 10 ml 2 times a day by mouth for 10 days, calcemin 1 tablet 1 time per day by mouth for 25 days. Treatment results: bacteriological examination of breast milk allocated: St. saprophyticus in the left and right breast at a concentration of 8×102and 3×102respectively (without pathology).

Table. The results of the treatment of staphylococcal-bakteriologie using ampicillin three-hydrate (I) and a method in combination Balance-Narine-f with calamina (II).

30
12345678910
No.Qty womenSave s breast scarm depositsNumber of women with a sterile breast milkDyspepsiaAllergic reaction
after 5 daysafter 10 daysafter 10 monthsafter 10 daysafter 10 monthsafter 10 daysafter 10 months
I20 (65%)6 (20%)19 (63,3%)12 (40%)6 (30%)1 (5%)8 (40%)6 (30%)
II180180 (100%)119 (66%)176 (97.8 per cent)169 (93,8%)3 (1,6%)2 (1,1%)01 (0,5%)

Thus, the proposed method for the treatment of staphylococcal-bakteriologie lactating women allows you to increase the number of women with a sterile breast milk, shortening the period of decrease in the content of staphylococci in the breast milk of nursing women and increasing the period of his sterility by reducing the permeability of the cell membrane, as well as the reduction of complications in the treatment of bakteriologie of lactating women.

Sources of information

1. Anokhin, VA Parent bacteriology and dysbiosis in children. / Vaananen, Sphagnicola, Sea // Actual problems of infectious pathology in children: Mat. III Congress of Pediatrics-infectious diseases of the Russian Federation. - M., 2004. - P.26.

2. Onishchenko GG status of the incidence of hospital-acquired infectious diseases and measures for their reduction. / Gennady Onishchenko // the decision of the fed the Federal service for supervision in the sphere of consumer rights protection and human welfare. - M., 2004. No. 3. - C.5.

3. Bacteriological control of breast milk: Methodical recommendations. / Znii MOH, Mniii, CLIV, research Institute of Pediatrics and pediatric surgery; Comp. V.I. Pokrovsky and others/. - M., 1984. - P.34.

4. Chadaev A.G. Acute purulent lactation mastitis. / Aghadi, Have. - M.: Medicine, 2003. - 128 S.

5. TU-9224-004-45448778-02. Bactericidal and bacteriostatic agent. / Appachan. - NSP from 26.03.04. Patent No. 2002118732.

6. The state register of medicines. - M., 2004. -T1. - S.

A method of treating staphylococcal-bakteriologie lactating women through the introduction of antibacterial agents, characterized in that as an antibacterial agent is injected balance-Narine-f and impose additional calcemin.



 

Same patents:

FIELD: organic chemistry, medicine.

SUBSTANCE: invention describes compounds of the general formula (I): or their salts wherein dotted line means a double bond optionally; L means fragment of group comprising -CH2-CH2-CH2-, -CH2-CH=CH- and CH2-C≡C-; each R2 and R3 means independently alkyl or halogenalkyl; R1 and R4 mean independently hydrogen atom, acyl group or hydroxy-protecting group under condition that at least one radical among R1 and R4 mean acyl group. Also, invention relates to using compounds of the formula (I) or their salts as medicinal agents used in treatment of hyperthyroidism, renal osteodystrophy or osteoporosis.

EFFECT: valuable medicinal properties of compounds.

28 cl, 4 tbl, 13 ex

FIELD: medicine, cardiology.

SUBSTANCE: in addition to conventional anti-ischemic and antithrombotic therapy one should introduce Calcium-D3 preparation that contains 200 IU cholecalciferol and 1250 mg calcium carbonate in one dosage due to correcting the dosage, multiplicity of introduction and duration of therapy course depending upon functional class of stenocardia and a patient's age and sex, as well. The implementation of the method provides efficient prophylaxis of osteoporosis in patients with chronic ischemic cardiac disease (CICD) of all functional classes and decreases the risk for the onset of side effects.

EFFECT: higher efficiency of prophylaxis.

2 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to high stable pharmaceutical component containing peptide of human parathyroid hormone or derivative thereof and acetic acid in amount of less than chemical equivalent in relates to peptide of human parathyroid hormone or derivative thereof. Due to low acetic acid level obtained pharmaceutical compositions have high stability and are comfortable in application.

EFFECT: nasal compositions with increased stability.

FIELD: medicine.

SUBSTANCE: method involves intravenous administration of 10% calcium chloride solution in patient lying in the horizontal position in the administration rate 0.8-1.0 ml per second for 7-10 s. Then a patient remains in the lying down position for 3-5 min. Method provides regulation of neurophysiological functions of body based on effect on vegetative nervous system receptors in this method of administration. Invention can be used as diagnostic, prophylactic and curative method in therapy, neurology, narcology, surgery and gynecology and in other fields of medicine.

EFFECT: improved method of administration.

FIELD: medicine, toxicology.

SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.

EFFECT: improved and enhanced effectiveness of treatment.

3 cl, 2 tbl

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to the development of a curative-prophylactic agent used in prophylaxis and treatment of diseases associated with deficiency of calcium in human body. The proposed composition comprises amaranthus milled dry leaves, calcium salts and phosphorus compound of mineral or organic origin. Also, the composition can comprise additionally dry Jerusalem artichoke or bilberry fruits, and filling agents also. As a filling agent the composition comprises substances chosen from the following group: chalk, chitin, chitosan, diatomite, tripolite, opoka, zeolite, talc, aerosil, calcium or magnesium stearate. Invention provides conversion of calcium component in ionic form due to addition of regulators of calcium metabolism in body to the main calcium component comprising in vegetable raw. The blood content of calcium in tested animals in experiments with oral administration of the proposed composition exceeds by 8-14% as compared with data obtained in animals with hypokinesia.

EFFECT: valuable medicinal properties of composition.

6 cl, 120 ex

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to producing a curative-prophylactic agent used in diseases associated with calcium deficiency in human body. Invention proposes a composition used in prophylaxis and treatment of diseases caused by calcium deficiency and comprising amaranthus dry leaves, vitamin D and phosphorus compounds of mineral or organic origin, wt.-%. Also, invention proposes a composition used in prophylaxis and treatment of diseases caused by calcium deficiency comprising amaranthus milled dry leaves, vitamin D, phosphorus compounds of mineral or organic origin, dry Jerusalem artichoke or bilberry fruits. Digestion of this composition allows providing the required concentration of blood calcium in its ionized form.

EFFECT: valuable medicinal properties of composition.

5 cl, 84 ex

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to production of a curative-prophylactic agent used in treatment of diseases associated with deficiency of calcium in human body. Invention proposes a group of inventions combined with the unit inventive idea and providing achievement of the unit technical result. Invention relates to a composition used in prophylaxis and treatment of diseases caused by calcium deficiency and this composition comprises amaranthus milled dried leaves, vitamin D, calcium salts and phosphorus compounds of mineral or organic origin. Also, invention relates to a composition used for prophylaxis and treatment of diseases caused by calcium deficiency, and comprising amaranthus milled dried leaves, vitamin D, calcium salts, phosphorus compounds of mineral or organic origin, dried Jerusalem artichoke or bilberry fruits. Intake of the proposed composition allows obtaining the required blood calcium concentration in its ionized form.

EFFECT: valuable medicinal properties of composition.

6 cl, 120 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to benzimidazole derivatives or their salts useful in medicine of the general formula (1): wherein R1 and R2 can comprise similar or different values and represent independently of one another hydrogen atom, halogen atom, cyano-group, hydroxyl group, alkyl group comprising 1-4 carbon atoms, alkoxy-group comprising 1-4 carbon atoms, trifluoromethyl group; A represents unsubstituted, linear alkylene group comprising 1-7 carbon atoms; E represents group -COOR3 comprising 1-6 carbon atoms; G represents unsubstituted, linear alkylene group comprising 1-6 carbon atoms; M represents a simple bond or -S(O)m- wherein m represents a whole number in the range 0, 1 or 2; J represents substituted or unsubstituted heterocyclic group comprising 4-10 carbon atoms and one heteroatom in ring taken among the group consisting of nitrogen atom or sulfur atom excluding unsubstituted pyridine ring; a substitute in indicated aromatic heterocyclic group is taken among halogen atom, cyano-group, linear alkyl group comprising 1-6 carbon atoms, linear alkoxy-group comprising 1-6 carbon atoms, trifluoromethyl group and trifluoromethoxy-group wherein one or more indicated substituted can be replaced by random positions in ring; X represents methane group (-CH=). Also, invention relates to a pharmaceutical composition used in inhibition of human chymase activity based on these compounds. Invention provides preparing new compounds and pharmaceutical composition based on thereof in aims for prophylaxis and/or treatment of inflammatory disease, cardiovascular disease, allergic disease, respiratory disease or osseous either cartilaginous metabolic disease.

EFFECT: valuable medicinal properties of compounds and composition.

14 cl, 3 tbl, 20 ex

The invention relates to medicine, biological substances and, in particular, to the use of biologically active substances extracted from plants of the family Dictyotacea for pharmaceutical, cosmetic and/or food compositions for influencing the synthesis of glycosylated elements in the extracellular matrix of tissues of animals and humans

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to phenylpyridazine derivative of general formula I , wherein R1 represents C1-C12-alkyl optionally comprising cyclic C3-C6-alkyl structures and optionally substituted by phenyl, which may be substituted by 1-2 halogen atoms; or C1-C12-alkenyl substituted by optionally halogen-substituted phenyl; R2 and R3, independently form each other, represent hydrogen, C1-C12-alkyl, C1-C12-hydroxyalkyl, C1-C12-dihydroxyalkyl, or C1-C12-alkynyl; or R2 and R3, together with adjacent nitrogen atom form 5-6-membered saturated heterocyclic group containing 1-2 nitrogen atoms and optionally oxygen atom, indicated heterocyclic group being optionally substituted by C1-C12-alkyl group, C1-C12-alkoxydicarboxylic group or phenyl-C1-C7-alkyl group; X, Y, and Z, independently form each other, represent hydrogen, halogen, optionally halogen(s)-substituted C1-C12-alkyl, C1-C12-alkoxy, C1-C12-alkylthio, C1-C12-alkylsulfinyl, C1-C12-alkylsulfonyl, or phenyl; and n is a number from 0 to 5; provided that R2 and R3 cannot be simultaneously hydrogen atoms or identical C1-C3-alkyl groups when R1 is benzyl or C1-C3-alkyl group; and salts of compounds I. Foregoing compounds manifest inhibitory activity against production of interleukin IL-1β being well dissoluble in water and characterized by good oral absorption. Invention also relates to therapeutical agent inhibiting production of interleukin 1β, pharmaceutical composition, employment of above-defined compounds, a method for treating disease caused by interleukin 1β production stimulation as well as methods for treating immune system disturbances, inflammatory conditions, ischemia, osteoporosis, or septicemia using above compounds.

EFFECT: expanded therapeutical possibilities.

22 cl, 4 dwg, 2 tbl, 217 ex

FIELD: medicine, gynecology, urology.

SUBSTANCE: on isolating Chlamydia out of infection foci and setting a preliminary diagnosis it is necessary to determine their sensitivity to different etiotropic preparations. Then it is important to sample a patient's blood followed by centrifuging and dividing it into plasma, erythrocytic mass and leukocytic suspension. Removed blood plasma should be substituted with physiological solution, and autoerythrocytes should be returned for a patient in physiological solution intravenously by drops. Autoleukocytic suspension should be activated with laser radiation of He-Ne laser at λ=0.63 mcm. Then it should be supplemented with etiotropic preparation moxyfloxacin to be intravenously injected for a patient. The procedure should be repeated daily for about 10-12 d. The innovation suggested enables to shorten the terms of interrupting the main clinical manifestations of the disease due to a purposeful transport of etiotropic preparation being of higher bacteriological efficiency in leukocytes activated with laser radiation, into primary (urogenital tract) and secondary (extraurogenital) foci of inflammation and, also, decrease side action of chemopreparations due to decreasing their course dosage.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: veterinary medicine.

SUBSTANCE: vaccine comprises as antigens cell suspension of pure cultures of a streptococcosus pathogen Streptococcus pneumoniae and an enterococcal pathogen Streptococcus fecalis isolated from suspension and prepared from damages organs of dead nutrias from the local epizootic focus wherein these cultures are grown separately in beef-extract broth with glucose with the concentration of microbial cells 4-5 billions in 1 cm3 and mixed in equal ratio. Also, vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumoniae isolated from a local epizootic focus in the nutrient medium with a titer 4-5 microbial cells in 1 cm3, 38.0-41.5; cell suspension of pure culture of enterococcal infection pathogen Streptococcus fecalis isolated from a local epizootic focus in the nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 38.0-41.5; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Vaccine is harmful and possesses high specificity and effectiveness.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: veterinary science.

SUBSTANCE: on finishing the lactation one should inject once antimicrobial preparation "Difumast" per 5 ml into all udder lobes and, additionally, intramuscularly one should inject immunomodulating "preparation "Dostim" at the dosage per 25 ml for the first time, and in 40-45 d - the second. The innovation enables to shorten the quantity of "difumast. The innovation enables to shorten the quantity of "Difumas" injected.

EFFECT: higher accuracy of prophylaxis.

1 tbl;, 1 ex

FIELD: medicine, oncology, biochemistry, antibiotics.

SUBSTANCE: invention relates to variants used in treatment of cancer. Method involves administration in a patient needing with such treatment of the effective dose of 9-amino-6-deoxy-5-hydroxytetracycline or its salt, or 9-nitro-6-deoxy-5-hydroxytetracycline or its salt for aims in treatment of breast cancer, melanoma, myeloma and prostate gland cancer. Invention provides anti-tumor, anti-metastatic effect and the elevating viability index based on inhibition of matrix-destructing metalloproteinase by indicated derivatives of tetracycline and without significant body weight loss.

EFFECT: valuable medicinal properties of derivatives, enhanced effectiveness of treatment.

4 cl, 5 tbl

FIELD: organic chemistry, antibacterial agents.

SUBSTANCE: invention relates to an agent used against acid-resistant microorganisms containing derivative of pyridone carboxylic acid as an active component, its pharmaceutically acceptable salt or its hydrate that elicits high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms. Invention describes agent used against acid-resistant microorganisms containing compound represented by the following formula (I) its salt or its hydrate as an active component wherein R1 represents cyclic alkyl group comprising 3-6 carbon atoms that can comprise substitute(s) chosen from halogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; A1 represents incomplete structure represented by the formula (2): wherein X2 represents halogen atom, alkyl group comprising 1-6 carbon atoms or alkoxy-group comprising 1-6 carbon atoms; A1, A2 and A3 form incomplete structure of the formula: in common with carbon atoms combined with them; X1 represents halogen atom; Y represents hydrogen atom; Z represents phenylpiperazine substitute. Invention provides synthesis of pyridone carboxylic acid eliciting high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms in combination with good pharmacokinetics indices and safety.

EFFECT: valuable biological property of agent.

10 cl, 9 tbl, 10 ex

FIELD: medicine, microbiology, clinical practice.

SUBSTANCE: claimed method includes determination of pectin antioxidant activity (AOA) by chemiluminescent method and on the base of AOA pectin bactericidal properties are evaluated, wherein increased AOA indicates increased bactericidal properties. Method of present invention makes it possible to decrease time of pectin antibacterial property determination from 3 days to 30 min.

EFFECT: method of decreased labor intensity and cost.

1 tbl, 1 dwg

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to a synthetic quinolone agent that is effective as medicinal agents, veterinary preparations, drugs used in fishing industry or as antibacterial preserving agents. Invention describes compound represented by the following general formula (I): as its separate isomers or their mixture, its salt and their hydrates wherein R1 represents cyclic alkyl group comprising 3-6 carbon atoms that can comprise a substitute chosen from halogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; R4 represents hydrogen atom, amino-group, hydroxyl group; A represents nitrogen atom or part of structure as given in the invention claim; each R5 and R6 represents independently alkyl group comprising 1-6 carbon atoms or hydrogen atom; n means a whole number 1 or 2. Also, invention describes antibacterial agent and therapeutic agent based on compounds of the formula (I) used in treatment of infectious disease, a method for preparing antibacterial agent, a method for preparing a medicinal agent used in treatment of infectious disease and using compound of the formula (I) for preparing an antibacterial agent and using compound of the formula (I) for preparing a medicinal agent used in treatment of infectious disease. Invention provides novel compounds possessing useful biological properties.

EFFECT: improved preparing method of agents, valuable medicinal properties of compounds and agents.

35 cl, 2 tbl, 15 ex

FIELD: chemistry of heterocyclic compounds, antibacterial agents.

SUBSTANCE: invention relates to agent used against acid-resistant microorganisms. Invention describes agent against acid-resistant microorganisms containing as an active component the compound represented by the general formula (1) or its hydrate wherein R2 represents hydrogen atom; R3 represents hydrogen atom; A1, A2 and A3 form incomplete structure of the formula: wherein A1 represent incomplete structure of the formula: wherein X2 and above described R1 can be combined to form six-membered cyclic structure comprising part of the parent nucleus wherein formed ring can comprise oxygen atom and, except for, can comprise alkyl group having 1-6 carbon atoms as a substitute; X1 represents halogen atom, hydrogen atom or amino-group; Y represents hydrogen atom; Z represents incomplete structure of the formula: . Agent elicits high antibacterial activity of broad spectrum and possesses good pharmacokinetics and safety also.

EFFECT: improved and valuable properties of agent.

3 cl, 9 tbl, 10 ex

FIELD: veterinary, vaccines.

SUBSTANCE: claimed vaccine contains as antigens pure culture cell suspension of causal organisms of salmonellosus Salmonella typhimurium and enterococcus infection Streptococcus fecalis, obtained by sampling of damaged organs of fallen nutrias from local epizootic focus, suspension preparation, seeding on differential diagnostic media, isolation of causal organism pure cultures. Culturing is carried out separately in meat-and-peptone broth with glucose at microbial cell concentration of 4-5 bln per 1 cm3, cells are mixed in ratio of 1:2, formalin and aluminum hydroxide are introduced in the next component ratio (mass %): pure culture cell suspension of causal organisms of salmonellosus Salmonella typhimurium isolated from local epizootic focus in broth with titer of 4-5 bln per 1 cm3 22.5-27.5; pure culture cell suspension of causal organisms of enterococcus infection Streptococcus fecalis isolated from local epizootic focus in broth with titer of 4-5 bln per 1 cm3 50.5-55.0-27.5; glucose 2.0-1.0; formalin 2.0-1.5; and balance: aluminum hydroxide.

EFFECT: associated vaccine with increased specificity and effectiveness without negative side effects.

1 tbl, 5 ex

FIELD: organic chemistry, vitamins.

SUBSTANCE: invention relates to novel triaromatic compounds, namely, analogs of vitamin D of the general formula (I): wherein values R1, R2, R3, X and Y are given in claim 1 of the invention claim. Also, invention relates to using these compounds in pharmaceutical compositions designated for treatment of the following diseases: (1) dermatological diseases associated with differentiation disturbance or proliferation of keratinocytes or sebocytes; (2) keratinization disorders; (3) dermatological diseases associated with disturbance of keratinization with inflammatory and/or immunoallergic components; (4) inflammatory diseases that don't represent keratinization disturbance; (5) cutaneous or epidermic expansion; (6) dermatological disorders, for example, vesicle dermatosis and collagenosis; (7) photoinduced or senile skin ageing, or for decreasing photoinduced pigmentations and keratosis, or any other pathologies associated with senile or photoinduced ageing; (8) skin healing and scar disturbances; (9) lipid function disturbances, such as acne hypersteatosis, simple seborrhea or seborrheic eczema; (10) dermatological diseases with immunologic component. Also, invention relates to cosmetic using the cosmetic composition for body and hair hygiene.

EFFECT: valuable medicinal and cosmetic properties of compounds.

16 cl, 3 tbl, 7 dwg, 10 ex

Up!